Allos Therapeutics, Inc. ALTH today announced that it has submitted
a request to the European Medicines Agency (EMA) for a re-examination of the
negative opinion issued in January by the EMA's Committee For Medicinal
Products for Human Use (CHMP) for conditional approval of FOLOTYN^ for the treatment of patients with peripheral T-cell
lymphoma whose disease has progressed after at least one prior systemic
therapy. PTCL comprises a biologically diverse group of aggressive, rare blood
cancers that have a worse prognosis than most other types of lymphoma,
including B-cell lymphoma. According to current CHMP guidelines, a final
opinion on the re-examination could be issued by the EMA within four to five
months.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in